Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PNLIP | P16233 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11548018 | 0.90 | MAOB (0.58) | ALDH1A1GAARAB9AMAPTHPGD | |
| SCHEMBL30356696 | 0.90 | MAOB (0.58) | ALDH1A1GAARAB9AMAPTHPGD | |
| SCHEMBL30816841 | 0.85 | LMNA (0.60) | RAB9APARP10PNLIPLMNAHSPB1 | |
| SCHEMBL21274603 | 0.85 | LMNA (0.60) | RAB9APARP10PNLIPLMNAHSPB1 | |
| SCHEMBL3024115 | 0.84 | PARP10 (0.67) | ALDH1A1PARP10PNLIPMAOBHSPB1 | |
| SCHEMBL756150 | 0.81 | MAPT (0.53) | RAB9AMAPTHPGDPARP10LMNA | |
| SCHEMBL9762032 | 0.81 | MAPT (0.53) | ALDH1A1GAARAB9AMAPTHPGD | |
| SCHEMBL9657442 | 0.81 | ALDH1A1 (0.49) | ALDH1A1GAARAB9AMAPTHPGD | |
| SCHEMBL3138940 | 0.81 | HPGD (0.79) | ALDH1A1GAARAB9AMAPTHPGD | |
| SCHEMBL3368165 | 0.80 | PTPN1 (0.57) | ALDH1A1RAB9AMAPTPARP10PNLIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986540-B1 | THE USE OF CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2005-02-16 | — | — | EP | claimed |
| US-6696442-B2 | THERAPY OF DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS IN A MAMMAL SUFFERING THEREFROM BY ADMINISTERING CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES, WHICH ACT AS BLOCKERS OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2004-02-24 | — | — | US | claimed |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | EURO-CELTIQUES S.A. | 2003-12-04 | — | — | US | claimed |
| US-6613803-B1 | Treating, preventing or ameliorating pain | EURO-CELTIQUE S.A. (LU) | 2003-09-02 | — | — | US | claimed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | claimed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | claimed |
| JP-2001526648-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-0986540-A4 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS INC (US) | 2001-07-11 | — | — | EP | claimed |
| EP-0986540-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | Cocensys, Inc. (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1998047869-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS, INC. (US) | 1998-10-29 | — | — | WO | claimed |
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | disclosed |
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | disclosed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | disclosed |
| EP-1173169-B1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | disclosed |
| US-6737418-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | EURO-CELTIQUE S.A. (LU) | 2004-05-18 | — | — | US | disclosed |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | EURO-CELTIQUE S.A. | 2003-04-10 | — | — | US | disclosed |
| US-6414011-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2002-07-02 | — | — | US | disclosed |
| EP-1173169-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000057877-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | ALDH1A1 91/4885GAA 2236/4885RAB9A 4389/4885 |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | GRIK5, GRIN3A, GRIK3 | ALDH1A1 284/4885GAA 2107/4885RAB9A 3883/4885 |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | ALDH1A1 91/4885GAA 2236/4885RAB9A 4389/4885 |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, CBR1, ALDH1A2 | ALDH1A1 97/4885GAA 2209/4885RAB9A 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.